Showing results (111-120 of 124) with videos related to

Sort By:
Pageof 13
Carcinogenesis|April 28, 2009
Dietary flavonoid fisetin induces a forced exit from mitosis by targeting the mitotic spindle checkpointAnna-Leena Salmela, Jeroen Pouwels, Asta Varis, et al.
Clinical Pharmacology and Therapeutics|November 3, 2022
Translating Academic Drug Discovery Into Clinical Development: A Survey of the Awareness of Regulatory Support and Requirements Among Stakeholders in EuropeMarko J Kallio, Viktoriia Starokozhko, Eleonora Agricola, et al.
European Journal of Clinical Nutrition|November 29, 2007
Neuropeptide Y polymorphism significantly magnifies diabetes and cardiovascular disease risk in obesity: the Hoorn StudyU Jaakkola, J Kallio, R J Heine, et al.
Neuropeptides|November 6, 2012
Neuropeptide Y polymorphism increases the risk for asthma in overweight subjects; protection from atherosclerosis in asthmatic subjects--the cardiovascular risk in young Finns studyU Jaakkola, T Kakko, M Juonala, et al.
Molecular Cancer Therapeutics|April 22, 2014
Centmitor-1, a novel acridinyl-acetohydrazide, possesses similar molecular interaction field and antimitotic cellular phenotype as rigosertib, on 01910.NaJenni H E Mäki-Jouppila, Leena J Laine, Jonathan Rehnberg, et al.
Oncotarget|March 5, 2016
Novel Mad2-targeting miR-493-3p controls mitotic fidelity and cancer cells' sensitivity to paclitaxelMahesh Tambe, Sofia Pruikkonen, Jenni Mäki-Jouppila, et al.
British Journal of Cancer|October 1, 2014
Excess of miRNA-378a-5p perturbs mitotic fidelity and correlates with breast cancer tumourigenesis in vivoS Winsel, J Mäki-Jouppila, M Tambe, et al.
Cytogenetics and Cell Genetics|June 14, 2002
cDNA cloning, expression studies and chromosome mapping of human type I serine/threonine kinase receptor ALK7 (ACVR1C)J Bondestam, M A Huotari, A Morén, et al.
Biochimie|October 25, 2016
Novel non-β-lactam inhibitor of β-lactamase TEM-171 based on acylated phenoxyanilineV G Grigorenko, I P Andreeva, M Yu Rubtsova, et al.
The Journal of Steroid Biochemistry and Molecular Biology|February 14, 2018
Discovery and development of ODM-204: A Novel nonsteroidal compound for the treatment of castration-resistant prostate cancer by blocking the androgen receptor and inhibiting CYP17A1Riikka Oksala, Anu Moilanen, Reetta Riikonen, et al.
Pageof 13